171 related articles for article (PubMed ID: 38050202)
21. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J
Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
[TBL] [Abstract][Full Text] [Related]
26. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer.
Guven DC; Sahin TK; Yildirim HC; Aktepe OH; Dizdar O; Yalcin S
Crit Rev Oncol Hematol; 2021 Dec; 168():103528. PubMed ID: 34800650
[TBL] [Abstract][Full Text] [Related]
27. CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review.
Fan X; Zhang J; Lu D
Medicine (Baltimore); 2023 Feb; 102(6):e32939. PubMed ID: 36820557
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
29. Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
Gao Y; Xi H; Wei B; Cui J; Zhang K; Li H; Cai A; Shen W; Li J; Rosell R; Chao J; Chen T; Klempner S; Qiao Z; Chen L
Front Oncol; 2019; 9():1222. PubMed ID: 31850190
[No Abstract] [Full Text] [Related]
30. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis.
Gögenur M; Hadi NA; Qvortrup C; Andersen CL; Gögenur I
Ann Surg Oncol; 2022 Dec; 29(13):8666-8674. PubMed ID: 35933546
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis.
Feng SN; Cen XT; Tan R; Wei SS; Sun LD
Transl Oncol; 2021 Jun; 14(6):101072. PubMed ID: 33744725
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
35. Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer.
Zhou H; Liu H; Li J; Wang J; Fu X; Li Y; Mao S; Du J
Genes Genomics; 2023 Aug; 45(8):1037-1046. PubMed ID: 37306927
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
Guo K; Lu J; Lou Y; Zheng S
Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
[TBL] [Abstract][Full Text] [Related]
37. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
[TBL] [Abstract][Full Text] [Related]
38. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies.
Wang S; Xu L; Wang Q; Li J; Bai B; Li Z; Wu X; Yu P; Li X; Yin J
World J Surg Oncol; 2019 Mar; 17(1):52. PubMed ID: 30885211
[TBL] [Abstract][Full Text] [Related]
39. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
40. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer.
Kim YW; Kim YH; Song Y; Kim HS; Sim HW; Poojan S; Eom BW; Kook MC; Joo J; Hong KM
Exp Mol Med; 2019 Aug; 51(8):1-10. PubMed ID: 31395853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
